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Abstract
This study was an active, prospective surveillance study of adults 18 years and older hospitalized with community-acquired pneumonia (CAP)
due to Streptococcus pneumoniae conducted at 21 hospitals in ten cities across the United States. This report describes the surveillance
methodology applied between October 7, 2013 and September 30, 2016, including the identification and description of surveillance areas
and populations at-risk for CAP hospitalization for estimation of incidence rates for selected study sites.

Introduction and Rationale
Community-acquired pneumonia (CAP) continues to be a one
of the leading causes of morbidity and mortality worldwide
[1-3]. The prevalence of Streptococcus pneumoniae in CAP,
especially non-bacteremic pneumococcal CAP, is likely
underestimated due to a lack of sensitive diagnostic assays
[4]. A traditional etiologic approach to subjects with CAP
requiring hospitalization includes obtaining blood and/or
sputum cultures. Although cultures are highly specific, their
sensitivity is low [5]. Despite difficulty in identifying etiologic
agents associated with CAP, S. pneumoniae was estimated to
cause nearly 600,000 cases of pneumonia among United States
(U.S.) adults >18 years of age in 2004, of which approximately
50% occurred in subjects aged >65 years and older [6].
In 2000, a 7-valent pneumococcal conjugate vaccine (PCV7)
was introduced into the U.S. infant immunization program. This
vaccine was replaced in 2010 with a 13-valent pneumococcal
conjugate vaccine (PCV13). This vaccination program has had
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a well-documented and significant public health impact among
those vaccinated [1, 7-12], and unvaccinated children and adults
have benefited from indirect (herd) protection derived from the
program [13, 14]. However, most of this indirect effect has been
reported for invasive pneumococcal disease; the impact in noninvasive pneumonia is not entirely understood.
One screening method for detecting infection by S. pneumoniae
is the BinaxNOW® kit provided by Alere™. This commonly
used rapid assay tests for the presence of pneumococcal
C-polysaccharide (C-PS) antigens in the urine using an
immunochromatographic membrane test kit. The sensitivity
of this assay is documented by the manufacturer as 86%
for bacteremic pneumococcal pneumonia [15]. While the
BinaxNOW® assay detects C-PS antigen, which is present in all
S. pneumoniae strains; it does not distinguish among different
pneumococcal serotypes.
More recently, a Luminex technology-based multiplex urinary
antigen detection (UAD) assay has demonstrated the ability
to simultaneously detect 13 different S. pneumoniae serotypespecific capsular polysaccharides in human urine [16]. These
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polysaccharides correspond to the 13 serotypes in PCV13 (1,
3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). A notable
advantage of this UAD assay is its ability to combine multiple
distinct beads, each conjugated to a different serotypespecific monoclonal antibody, in a single well with the urine
to be tested. This allows the detection of all 13 polysaccharides
simultaneously using only a small sample volume. The UAD
assay has demonstrated greater sensitivity than culture or
BinaxNOW® urinary antigen detection and excellent specificity
in a convenience sample obtained from 776 subjects with
radiographically confirmed CAP [16], and in a separate
prospective study of adults with radiographically-confirmed
pneumonia [17]. In a study conducted in 2010, the use of the
UAD assay helped to demonstrate PCV7 associated serotypes
were still prevalent among adults aged ≥50 years with CAP,
representing 26.6% of all S. pneumoniae serotypes detected
[19]. Nevertheless, the burden of both non-invasive and invasive
pneumococcal disease in adults with pneumonia after the
introduction of PCV13 remains unclear.
To provide more contemporary information about the
proportion of radiographically-confirmed CAP in adults (≥18
years old) caused by S. pneumoniae, a large epidemiological
study was undertaken. Pneumococcal serotypes were identified
using the serotype-specific UAD assay and standard culture
methods. Serotype distribution was estimated for the total
population and incidence was calculated at selected sites. In
this report we describe the methodology of the study design,
including the specifics of subject selection and study procedures.

Objectives
The primary objective of this study was to estimate the
proportion of pneumonia cases caused by PCV13 S. pneumoniae
serotypes among adults ≥18 years of age hospitalized with
radiographically-confirmed pneumonia. Secondary objectives
included: 1. Description of the full distribution of detected S.
pneumoniae serotypes; 2. Estimation of the incidence rate of
CAP overall and CAP caused by S. pneumoniae (SP+ CAP) for
sites where a population denominator could be established; and
3. Description of the differences in detection of S. pneumoniae
by culture, BinaxNOW® and UAD assay.

Study Design

enrollment); and 3) able and willing to provide urine samples
for diagnostic evaluation.
Exclusion criteria
Subjects were excluded from the study if they: 1) were
transferred from another inpatient healthcare facility after
already being hospitalized for 48 hours or more; 2) had a
diagnosis of hospital acquired pneumonia (ie, developed signs
and symptoms of pneumonia after being hospitalized for 48
hours or more); and 3) were previously enrolled in this study
within the past 30 days.
Enrollment Sites
This study enrolled subjects from 21 hospitals in 10 US cities
(Akron, OH, Chicago, IL, Detroit, MI, Louisville, KY, Nashville,
TN, Norfolk, VA, Houston, TX, Las Vegas, NV, San Diego, CA
and Worcester, MA) (Table 1). Pneumonia incidence was
calculated at sites which were able to establish a population
denominator: Louisville, KY (nine hospitals), Nashville, TN
(one hospital) and Chicago, IL (one hospital).

Table 1. Details of 21 enrolling hospital centers
Institution Name

City

Number of Adult
Beds

State

Setting

VA

Not-for-profit
community based
teaching hospital

CA

Community Hospital

532

CA

Community Hospital

343

CA

Community Hospital

Sentara Norfolk
General Hospital

Norfolk

Sharp Grossmont
Medical Center
Sharp Chula Vista
Medical Center
Tri-City
Medical Center

La Mesa
(San Diego)
Chula Vista
(San Diego)
Oceanside
(San Diego)

Northwestern University
Feinberg School of Medicine

Chicago

IL

University of Louisville
Hospital

Louisville

KY

Louisville

KY

Teaching Hospital

109

Louisville
Louisville
Louisville
Louisville
Louisville
Louisville
Louisville

KY
KY
KY
KY
KY
KY
KY

Community Hospital
Community Hospital
Community Hospital
Community Hospital
Community Hospital
Community Hospital
Community Hospital

412
298
859
127
432
373
468

Worcester

MA

Academic Hospital

Detroit

MI

Robley Rex VA
Medical Center
Jewish Hospital
Saint Mary & Elizabeth Hospital
Norton Hospital
Norton Brownsboro Hospital
Norton Audubon Hospital
Norton Suburban Hospital
Baptist Hospital East
UMASS Memorial
Medical Center
Detroit Receiving Hospital
Sinai-Grace Hospital

Detroit

MI

Sunrise Hospital and
Medical Center

Las Vegas

NV

Summa Health System

Akron

OH

Vanderbilt University
Medical Center

Nashville

TN

University of Texas
Medical School at Houston

Houston

TX

500

397

Urban
Academic/teaching
Not-for-Profit Hospital
Urban
Academic/teaching
Not-for-Profit Hospital

854
384

779

Academic Urban
Medical Center
Academic Urban
Medical Center

248
299

Community Hospital

638

Community-based
teaching hospital
Academic Hospital in
urban setting
Not for profit,
University-affiliated
tertiary care center

542
906

This prospective, multicenter, surveillance study was conducted
at 21 hospitals in 10 geographically dispersed U.S. cities between
October 7th, 2013 and September 30th 2016. The institutional
review board (IRB)/independent ethics committee (IEC) at
each participating site reviewed and approved the protocol and
informed consent form before any subjects provided consent.

Incidence surveillance sites

Inclusion criteria

Louisville

Subjects 18 years of age and older who presented to a study
hospital were eligible for enrollment if they met the following
criteria: 1) the presence of 2 or more of the following a) fever
(oral temperature > 38°C/100.4°F or tympanic temperature
>38.5°C/ 101.2°F) or hypothermia (<35.5°C) within 24 hours
of enrollment b) chills or rigors c) pleuritic chest pain d) cough
e) sputum production f) dyspnea g) tachypnea h) malaise
i) abnormal auscultatory findings; 2) radiographic finding
consistent with pneumonia (chest radiograph or chest computed
tomography scan obtained no more than 72 hours prior to study

The surveillance area for Louisville is Jefferson County, located
in the northwest region of the state of Kentucky. All nine
hospitals providing adult hospitalization for pneumonia were
included in this study. The adult census population of Louisville
was used as the denominator for incidence rate calculations,
while the numerator was derived from the number of Louisville
residents hospitalized for CAP. The annual population incidence
rate per 100,000 adults was estimated for this catchment area.
Although all eligible cases were identified, approximately 20%
of patients did not consent to participate in the study (Table 2).

ULJRI Vol 1, (4) 2017

733

36

This 20% of unconsented CAP patients will be factored into the
numerator for this site.
The comprehensive management group in Louisville included
over 60 team members performing functions that spanned
all aspects of study management. The overall accountability
remained with the Principal Investigator, however daily
operations were led by the coordinating center manager.
Study related activities were stratified into four categories: 1)
compliance/administration, 2) data science/infrastructure, 3)
clinical operations and 4) laboratory/biorepository operations.
The compliance and administration group managed budgets,
payments, invoicing, IRB approvals, issues of informed consent,
and compliance with all federal, state, local and university study
conduct requirements. The data science and infrastructure
group was responsible for maintaining security of the data
during collection, transmission, and storage, management
of data quality monitoring meetings, development and
implementation of the Data Security Plan, and implementing
real-time reporting of enrollment across the coordinating
center. The clinical operations team was responsible for the
development of Standard Operating Procedures (SOPs) for
clinical operations, the manual of operations, development
of data collection forms and training in their use, study team
management and training, ensuring adequate supply of
materials needed for daily operations, establishing tools for
assessment of coordinators as well as testing procedures and
processes. Laboratory and biorepository operations developed
the process for specimen collection, analysis, and tracking and
documented receipt, shipment, and storage of study specimens.
Chicago and Nashville
The surveillance centers for Nashville and Chicago are located
at Vanderbilt University Medical Center and Northwestern
Memorial Hospital, respectively. Each represents only one
of multiple hospitals in the Nashville and Chicago regions,
respectively. Both are large urban hospitals serving adult
general medical and surgical patients. For the Nashville site,
patients were enrolled from 9 counties around Nashville area
(Cheatham, Davidson, Dickson, Montgomery, Robertson,
Rutherford, Sumner, Trousdale, and Williamson). Eight other
hospitals in the area treat adult pneumonia. Thus, the cases
enrolled at this site did not represent all cases in this catchment
area (nine counties); however estimations of incidence
were performed by applying market share estimation. The
Tennessee Hospital Discharge Data System (HDDS) database
was used to determine the percentage (market share) of CAP
hospitalizations contributed by Vanderbilt University hospital
among the total hospitals within the nine counties. All hospitals
in Tennessee are required to report discharge diagnoses for each
hospitalization, emergency department visit and outpatient
clinic visit to the HDDS system.
The incidence from the Chicago site was also calculated using the
market share method. COMPdata-Illinois Health and Hospital
Association provided the market share for Northwestern
Memorial Hospital pneumonia hospitalizations among Cook
County residents [19]. Approximately 32% of CAP patients did
not provide consent for enrollment in the study. This will be
factored into the incidence calculation for this site.

Table 2. Estimated catchment area denominator and
market share for incidence calculations
Year 1 date
Market share ages 18-64 years
Market share ages 65+
Year 2 date
Market share ages 18-64 years
Market share ages 65+

Chicago*
Oct. 2013-Sept. 2014
4.57%
3.63%
Oct. 2014-Sept. 2015
4.30%
3.47%

Nashville*
Nov. 2013-Oct. 2014
14.30%
7.23%
Nov. 2014-Oct. 2015
13.39%
6.38%

Louisville**
June 2014-May 2015
100%
100%
June 2015-May 2016
100%
100%

*Adjusted for an estimated 32% non-consented rate.
**Adjusted for a 20% non-consented rate.

Subjects
Subjects with suspected pneumonia who provided written
informed consent were screened for inclusion in the study.
Subjects were actively identified during normal day to day
procedures at participating centers.
Subject recruitment
included at a minimum a daily review of the emergency
department and admission records for potential subjects, as
well as doctor-to-doctor communication regarding the study.
Subjects identified outside of normal daily procedures were also
contacted, evaluated and recruited on the following calendar
day.
Sites used for the estimation of incidence employed several
approaches to ensure complete identification of all patients
meeting study criteria. In Louisville, the Clinical Research
Coordinating Center at the University of Louisville Division
of Infectious Diseases operationalized the project across all
nine participating hospitals. Adult patients presenting to
participating hospitals with the following conditions were
assessed via electronic medical records (EMR) for inclusion
in the study: respiratory failure, congestive heart failure,
aspiration, stroke, urinary tract infection, confusion, and altered
mental status. Initial radiographic findings were reviewed for
patients meeting any of the criteria. Patients with findings
consistent with pneumonia were approached for inclusion in the
study.
Eligible patients presenting in Nashville were identified
electronically utilizing the EMR system at Vanderbilt University
Medical Center (StarPanel®). The system was programmed to
alert the study team of chest x-ray and CT findings potentially
consistent with pneumonia. Research team members stationed
in the emergency department were then dispatched to further
evaluate patients for inclusion. In Chicago, individual research
coordinators screened hospital admission records daily for
patients meeting inclusion criteria. Identified patients were
subsequently contacted for further evaluation for study
inclusion.

Study Procedures
Results of chest imaging (X-ray or CT scan) performed per the
standard of care were recorded. Images obtained within 72
hours prior to the signing of informed consent could be used in
addition to those obtained at the time of hospitalization. Upon
confirmation of eligibility, further information was collected,
including demographic information, pneumonia severity
index (PSI) and medical history (including chronic obstructive
pulmonary disease [COPD], asthma, congestive heart failure
[CHF], coronary artery disease, chronic kidney disease, diabetes
and liver disease, immunosuppressive therapy, autoimmune
disease, HIV/AIDS, solid and hematologic tumors and organ
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transplantation). Self-reported vaccination status was collected
for influenza (within the previous year) and pneumococcal
vaccine exposure (within the previous five years).
Urine was collected via micturation as soon as possible
following the signing of the informed consent. Urine samples
were frozen and stored for subsequent UAD and BinaxNOW®
testing. If a blood culture was not obtained as standard of care,
it was performed by the study team within 24 hours of study
enrollment. Available results of blood and respiratory cultures
(sputum, tracheal aspirate, bronchial washing, pleural fluid,
etc.), including antibiotic susceptibility testing, were recorded.
S. pneumoniae isolates obtained from the sites were sent to a
central laboratory for confirmation of the pathogen and serotype
identification.
Assessments
Subjects had a final diagnosis recorded based on available data,
including both study and standard of care exams, procedures
and tests through hospital discharge or hospitalization day 10,
which ever occurred first. Principal investigators confirmed
whether the subject had clinical and radiographically confirmed
pneumonia and recorded the subjects’ vital status. A final
assessment was conducted to determine subject vital status at
30 days post-enrollment, either by phone call or follow-up as
standard of care.
Urine assays
The BinaxNOW® antigen test is a rapid assay for the qualitative
detection of S. pneumoniae antigen in the urine of patients
with pneumonia [2o]. The UAD is a validated limit assay with
defined positivity cut-off limits and is based on the ability of
individual serotype-specific monoclonal antibodies to detect the
polysaccharides of the 13 serotypes covered by PCV13 in urine.

Statistics
Sample Size Determination
The primary objective of this study was to estimate the
proportion of adults hospitalized with CAP infected with a
PCV13 S. pneumoniae serotype. Sample size determination was
based on the 95% confidence interval around this proportion.
With a sample size of 216 subjects at each site and an expected
proportion of 0.10, an approximate 95% confidence interval will
be ±0.04 at a given site.
Analyses
The primary study analysis population was comprised of subjects
meeting all inclusion criteria, with a final diagnosis of CAP, and
no evidence of pneumococcal vaccination within 30 days prior
to enrollment. A subject with SP+CAP was defined as a patient
meeting criteria for CAP and with S. pneumoniae identified by
UAD, BinaxNOW®, or cultures. The primary endpoint of this
study was the proportion of subjects with clinically (confirmed
diagnosis of CAP at final assessment) and radiographicallyconfirmed CAP who had any of the S. pneumoniae serotypes
from the PCV13 vaccine based on the UAD assay or culture. This
proportion was summarized for all sites with 95% confidence
interval using the exact method.
The proportion of subjects with PCV13 vaccine type (VT) and
non-vaccine type (non-VT) S. pneumoniae was summarized by
site and geographic region in the full analysis population. To

examine the differences in detection by the different methods,
the proportion of subjects with detection of S. pneumoniae
by culture, BinaxNOW®, and UAD assay were summarized
by method (among patients with tests performed). Serotype
distribution of S. pneumoniae isolates was described by
determining the proportion of subjects for each of the S.
pneumoniae serotypes. Antibiotic resistance rates of S.
pneumoniae isolates were also determined.
Incidence
For sites with well-defined catchment areas, annual pneumonia
incidence rates per 100,000 at risk population were estimated.
All incidence rates were computed separately, as well as
an annualized rate of the two study years combined. The
numerators for each of the incidence rate calculations were the
respective numbers of cases during the designated time periods
as operationalized in the case definitions; the denominators
were the corresponding estimated population figures provided
by the US census bureau. Ninety-five percent confidence
intervals, based on the Poisson distribution were computed for
all incidence rates. Incidence rates were also computed for keysub-groups (e.g., age and gender).

Discussion
This is the largest surveillance study for S. pneumoniae
CAP among hospitalized adults in the U.S. with the ability to
measure non-invasive pneumococcal disease and identify causal
serotypes. The results of this prospective study will provide
epidemiologic information concerning the current burden of
CAP due to S. pneumoniae, including the current distribution of
pneumococcal serotypes and their incidence based on population
surveillance. Previous analyses of S. pneumoniae incidence [2,
21] in CAP have been performed in the U.S.; however, they were
conducted before widespread use of PCV13 in children, and
before the increasing use of PCV13 among adults seen in recent
years. Current data on S. pneumoniae serotype distribution in
CAP are also limited, as few studies have measured both noninvasive and invasive disease utilizing non-culture methods to
identify S. pneumoniae in adults.
Importantly, the population surveillance conducted in the
Louisville sites provides virtually complete capture of the
population at risk for CAP in this area, and therefore yields an
incidence rate representative of 100% of the market share in the
Louisville area. Market share methodologies for the estimates of
incidence in Chicago and Nashville hospital sites (~5-15% market
share at one hospital in each location) may yield incidence rates
affected by potential differences in patient population at each
hospital in the catchment area and an inability to capture the
entire population at risk.
In conclusion, the novel methodology of this study allows for
a more accurate estimation of the current incidence of PCV13isolates among hospitalized patients with CAP in the United
States via the use of the UAD assay. In addition, information
on non-PCV13 serotypes is being gathered via culture methods,
along with each subject’s PCV13 vaccination status. This
may have implications both for evaluation of PCV13 vaccine
effectiveness and non-vaccine serotypes likely to be of increasing
importance in the near future.

ULJRI Vol 1, (4) 2017

38

Acknowledgements: Editorial support was provided by Scott
Vuocolo, PhD (Pfizer). The authors wish to acknowledge the
contribution of Scott Overcash to the study and manuscript.
Funding Source: This study was funded by Pfizer, Inc.

References

11.

12.

1.

Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M,
Biscardi S et al. Early impact of 13-valent pneumococcal
conjugate vaccine on community-acquired pneumonia in
children. Clin Infect Dis. 2014 Apr;58(7):918–24.
2. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R,
Bramley AM et al.; CDC EPIC Study Team. CommunityAcquired Pneumonia Requiring Hospitalization among
U.S. Adults. N Engl J Med. 2015 Jul;373(5):415–27.
3. Prina E, Ranzani OT, Torres A. Community-acquired
pneumonia. Lancet. 2015 Sep;386(9998):1097–108.
4. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M,
O’Brien KL, Andreo F et al.; AGEDD Adult Pneumococcal
Burden Study Team. Estimating the burden of
pneumococcal pneumonia among adults: a systematic
review and meta-analysis of diagnostic techniques. PLoS
One. 2013;8(4):e60273.
5. Rosón B, Carratalà J, Verdaguer R, Dorca J, Manresa F,
Gudiol F. Prospective study of the usefulness of sputum
Gram stain in the initial approach to community-acquired
pneumonia requiring hospitalization. Clin Infect Dis. 2000
Oct;31(4):869–74.
6. Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA,
Moore MR et al. Healthcare utilization and cost of
pneumococcal disease in the United States. Vaccine. 2011
Apr;29(18):3398–412.
7. Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S,
Greenberg D, Dagan R. Near-elimination of otitis media
caused by 13-valent pneumococcal conjugate vaccine
(PCV) serotypes in southern Israel shortly after sequential
introduction of 7-valent/13-valent PCV. Clin Infect Dis.
2014 Dec;59(12):1724–32.
8. Knoll MD. Preliminary Estimates of Adult Pneumococcal
Disease Burden in the United States in the Post
13-valent pneumococcal conjugate vaccine (PCV-13)
Era. 10th International Symposium on Pneumococci and
Pneumococcal Diseases (ISPPD-10); June 26-30; Glasgow,
Scotland 2016.
9. Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton
SI. Direct and indirect effects of PCV13 on nasopharyngeal
carriage of PCV13 unique pneumococcal serotypes in
Massachusetts’ children. Pediatr Infect Dis J. 2014
May;33(5):504–10.
10. Pilishvili T, Gierke R, Farley MM, Schaffner W, Thomas
AR, Reingold A et al., editors. Direct and Indirect Impact
of 13-valent Pneumococcal Conjugate Vaccine (PCV13)
on Invasive Pneumococcal Disease (IPD) in the U.S.
Era. 10th International Symposium on Pneumococci

13.

14.

15.
16.

17.

18.

19.

20.
21.

22.

and Pneumococcal Diseases (ISPPD-10);; June 26-30;
Glasgow, Scotland 2016.
Chan KC, Subramanian R, Chong P, Nelson EA, Lam HS,
Li AM et al. Pneumococcal carriage in young children
after introduction of PCV13 in Hong Kong. Vaccine. 2016
Jul;34(33):3867–74.
Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson
S, Gault S et al. Polysaccharide conjugate vaccine against
pneumococcal pneumonia in adults. N Engl J Med. 2015
Mar;372(12):1114–25.
Miller E, Andrews NJ, Waight PA, Slack MP, George RC.
Herd immunity and serotype replacement 4 years after
seven-valent pneumococcal conjugate vaccination in
England and Wales: an observational cohort study. Lancet
Infect Dis. 2011 Oct;11(10):760–8.
Davis SM, Deloria-Knoll M, Kassa HT, O’Brien KL. Impact
of pneumococcal conjugate vaccines on nasopharyngeal
carriage and invasive disease among unvaccinated people:
review of evidence on indirect effects. Vaccine. 2013
Dec;32(1):133–45.
BinaxNow® [package insert]. Scarborough, ME: Alere
Scarborough, Inc.; 2012.
Pride MW, Huijts SM, Wu K, Souza V, Passador S, Tinder
C et al. Validation of an immunodiagnostic assay for
detection of 13 Streptococcus pneumoniae serotypespecific polysaccharides in human urine. Clin Vaccine
Immunol. 2012 Aug;19(8):1131–41.
Pride MW, Huijts SM, Wu K, Souza V, Passador S, Tinder
C et al. Validation of an Immunodiagnostic Assay for
the Detection of 13 S. pneumoniae Serotype-Specific
Polysaccharides in Human Urine. Clin Vaccine Immunol.
2012;19(8):1131–41.
Sherwin RL, Gray S, Alexander R, McGovern PC, Graepel
J, Pride MW et al. Distribution of 13-valent pneumococcal
conjugate vaccine Streptococcus pneumoniae serotypes
in US adults aged ≥50 years with community-acquired
pneumonia. J Infect Dis. 2013 Dec;208(11):1813–20.
Sherwin RL, Gray S, Alexander N, McGovern P, Graepel J,
Pride MW, Purdy J, Jr TM. Distribution of PCV13-serotype
Streptococcus pneumoniae in Adults Aged≥ 50 Years
Presenting to Select US Hospitals with RadiographicallyConfirmed Community-Onset Pneumonia. ID Week, San
Diego. 2012 Oct
COMPdata Informatics. Available from: https://www.
compdatainfo.com/About-Us.aspx
Lasocki S, Scanvic A, Le Turdu F, Restoux A, Mentec
H, Bleichner G et al. Evaluation of the Binax NOW
Streptococcus pneumoniae urinary antigen assay in
intensive care patients hospitalized for pneumonia.
Intensive Care Med. 2006 Nov;32(11):1766–72.
Broulette J, Yu H, Pyenson B, Iwasaki K, Sato R. The
incidence rate and economic burden of communityacquired pneumonia in a working-age population. Am
Health Drug Benefits. 2013 Sep;6(8):494–503.

ULJRI Vol 1, (4) 2017

39

